- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: LDP-341, MLM341, NSC 681239,PS-341 中文名稱:硼替佐米
此產(chǎn)品請避光密封保存。
Bortezomib是有效的蛋白酶抑制劑,Ki為0.6 nM。它對腫瘤細胞表現(xiàn)出良好的選擇性。Bortezomib可抑制 NF-κB 并誘導(dǎo) ERK 的磷酸化從而抑制cathepsin B并在卵巢癌和其他固體腫瘤中抑制自噬的催化過程。
Bortezomib Chemical Structure
CAS: 179324-69-7
相關(guān)靶點 | 20S proteasome | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | MG132 Epoxomicin (BU-4061T) Celastrol Oprozomib ONX-0914 (PR-957) Delanzomib VR23 Marizomib (Salinosporamide A) PI-1840 | 點擊展開 |
相關(guān)化合物庫 | FDA藥物庫 天然產(chǎn)物庫 已知活性藥物庫-I 蛋白酶抑制劑庫 泛素化化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
human PBMC | Function Assay | 100 nM | 24 h | Induces IL-8 release | 25791477 |
U937 | Function Assay | 100 nM | 6 h | Induces IL-8 expression in LPS-stimulated U937 macrophages | 25791477 |
HH | Migration Assay | 100 nM | 24 h | Reduces cell migration by 80–91% | 25681335 |
Hut-78 | Migration Assay | 100 nM | 24 h | Reduces cell migration by 80–90% | 25681335 |
HH | Function Assay | 100 nM | 24 h | downregulates TGF-β1 and IL-12 expression | 25681335 |
H9 | Function Assay | 100 nM | 24 h | Downregulates TGF-β1 and IL-11 expression | 25681335 |
Hut-78 | Function Assay | 100 nM | 24 h | Downregulates TGF-β1 and IL-10 expression | 25681335 |
H1299 | Apoptosis Assay | 80 nM | 24 h | Sensitizes NSCLC cells to MSC-derived iC9-induced apoptosis | 25323693 |
BLM | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 |
A375 | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 |
BLM | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 |
A375 | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 |
RAW 264.7 | Growth Inhibition Assay | 100 nM | 48 h | Reduces cell viability? | 22427154 |
SNK-6 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 |
KAI-3 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 |
SNT-16 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 |
SNT-13 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 |
KHYG-1 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 |
KAI-3 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 |
Jurkat | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 |
SNT-16 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 |
KHYG-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
SNK-6 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
KAI-3 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
Jurkat | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
SNT-16 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
SNT-13 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
BJAB | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
LCL-2 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
LCL-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
Raji | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability? | 21170988 |
BaF/3-p210 | Function Assay | 6 nM | 24 h | Reduces the phosphorylation and the activity of Rb | 20305692 |
BaF/3-p210 | Function Assay | 6 nM | 48 h | Induces a slight G1 cell-cycle arrest | 20305692 |
BaF/3 | Function Assay | 6 nM | 48 h | Induces a great G1 cell-cycle arrest | 20305692 |
TCC-S | Growth Inhibition Assay | 100 nM | 48 h | IC50=2.8 nM | 20305692 |
BaF/3-p210 | Growth Inhibition Assay | 100 nM | 48 h | IC50=4.7 nM | 20305692 |
BaF/3 | Growth Inhibition Assay | 100 nM | 48 h | IC50=6.2 nM | 20305692 |
RPMI 8226 | Function Assay | 20 nM | 8 h | Induces DNA synthesis | 19436050 |
OPM2 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
INA6 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
OPM1 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
U266 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
MM.1S | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
RPMI 8226 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 |
CHLA-255 | Function Assay | 10 nM | 24 h | Modestly reduces cells in the G0/G1 phase | 17689684 |
NB-1691 | Function Assay | 10 nM | 24 h | Significantly reduces cells in the G0/G1 phase | 17689684 |
SK-N-AS | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 10% | 17689684 |
CHLA-255 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 2% | 17689684 |
NB-1691 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 5% | 17689684 |
HKe-3 | Apoptosis Assay | 50 nM | 48 h | Induces cell apoptosis | 16778179 |
HCT116 | Apoptosis Assay | 50 nM | 48 h | Induces cell apoptosis | 16778179 |
T29Kt1 | Apoptosis Assay | 50 nM | 48 h | Induces cell apoptosis | 16778179 |
T29 | Apoptosis Assay | 50 nM | 48 h | Induces cell apoptosis | 16778179 |
LNCap-Pro5 | Function Assay | 1 μM | 4 h | Stabilizes p53 | 14612532 |
H460 | Function Assay | 100 nM | 24 h | Induces G2-M-phase arrest and tubulin assembly-disassembly | 12631620 |
H322 | Growth Inhibition Assay | 10 μM | 72 h | IC50=620 nM | 12631620 |
H358 | Growth Inhibition Assay | 10 μM | 72 h | IC50=70 nM | 12631620 |
H460 | Growth Inhibition Assay | 10 μM | 72 h | IC50=100 nM | 12631620 |
RPMI8226/LR5 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
U266/dox4 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
U266/LR7 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
WAD-1 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
ARH77 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
U266 | Growth Inhibition Assay | 500 ng/ml | 48 h | Inhibits cell growth | 12631619 |
H460 | Function Assay | 10 μM | 24 h | Induces Bcl-2 phosphorylation and cleavage correlated with G2-M phase arrest | 12492117 |
UM-SCC-11B | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
UM-SCC-9 | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
B7E3 | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
B4B8 | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
PAM-LY2 | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
PAM 212 | Growth Inhibition Assay | 100 nM | 72 h | Inhibits cell viability | 11350913 |
PAM-LY2 | Function Assay | 100 nM | 12 h | Inhibits NF-κB activation | 11350913 |
Hs Sultan | Growth Inhibition Assay | 100 nM | 48 h | IC50=20 nM | 11306489 |
IM-9 | Growth Inhibition Assay | 100 nM | 48 h | IC50=6 nM | 11306489 |
U266 | Growth Inhibition Assay | 100 nM | 48 h | IC50=3 nM | 11306489 |
LR5 | Growth Inhibition Assay | 100 nM | 48 h | IC50=20 nM | 11306489 |
MR20 | Growth Inhibition Assay | 100 nM | 48 h | IC50=20 nM | 11306489 |
Dox40 | Growth Inhibition Assay | 100 nM | 48 h | IC50=40 nM | 11306489 |
RPMI8226 | Growth Inhibition Assay | 100 nM | 48 h | IC50=30 nM | 11306489 |
OVCA 429 | Function Assay | 300 nM | 48 h | Disrupts intact multicellular tumor spheroids | 10999766 |
MCF-7 | Cytotoxic Assay | 50 μM | 48 h | Kills cells by more than 99% | 10499643 |
HeLa | Function assay | 5 nM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 5 nM after 8 hrs by luciferase assay | 21186794 |
HeLa | Function assay | 1 uM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 1 uM after 8 hrs by luciferase assay | 21186794 |
LN229 | Function assay | 100 nM | 1 hr | Inhibition of HIF1alpha expression in human LN229 cells assessed as reduction of HIF-1alpha accumulation at 100 nM preincubated for 1 hr under normoxia condition followed by 24 hrs incubation under hypoxia condition by Western blotting | 21831638 |
LN229 | Function assay | 20 uM | 1 hr | Inhibition of hypoxia-induced HIF1alpha accumulation in human LN229 cells at 20 uM after 1 hr preincubation measured after 24 hrs by Western blot analysis | 22032632 |
U1 | Function assay | 10 uM | 24 hr | Inhibition of NF-kappaB-mediated viral replication in Homo sapiens (human) U1 cells infected with X4 tropic HIV1 NL4-3 at 10 uM after 24 hr by RT-PCR analysis in presence of TNF-alpha | 23290051 |
Calu6 | Function assay | 10 uM | 18 hrs | Inhibition of His-tagged Frataxin (unknown origin)/Ubiquitin interaction expressed in human Calu6 cells assessed as increase in frataxin (1-210) precursor level at 10 uM after 18 hrs by Western blotting analysis | 23506486 |
HEK293 | Cytotoxicity assay | 0.0001 uM to 100 uM | 48 hrs | Cytotoxicity against human HEK293 cells expressing murine FAP at 0.0001 uM to 100 uM after 48 hrs by CellTiter-Blue assay | 23594271 |
A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of poly-ubiquitinated proteins at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 |
A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as stabilization of p53 at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 |
A549 | Function assay | 0.025 to 0.1 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of Noxa at 0.025 to 0.1 uM after 24 hrs by immunoblot assay | 25639862 |
MCF7 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MCF7 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 |
MDA-MB-468 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MDA-MB-468 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 |
SK-N-SH | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human SK-N-SH cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 |
MYCN2 | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human MYCN2 cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 |
U266 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human U266 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 |
RPMI8226 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human RPMI8226 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 |
NCI-H929 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human NCI-H929 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 |
HL60 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human HL60 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 |
SUP-B15 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 |
SEM | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human SEM cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 |
SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by by FACS analysis | 30365892 |
SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by fluorescence microscopic method | 30365892 |
HL60 | Function assay | 100 nM | Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells at 100 nM | 19655762 | |
AMO1 | Antitumor assay | 1 mg/kg | Antitumor activity against human AMO1 cells xenografted in nude SCID beige mouse assessed as tumor growth inhibition at 1 mg/kg, iv administered twice per week | 26565666 | |
MDA-MB-231 | Function assay | 1 uM | Inhibition of trypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | |
MDA-MB-231 | Function assay | 1 uM | Inhibition of caspase like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | |
MDA-MB-231 | Function assay | 1 uM | Inhibition of chymotrypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | |
FSCLL | Cytotoxicity assay | 24 hrs | CC50 = 0.004 μM | 21634429 | |
HEK293 | Cytotoxicity assay | 24 hrs | CC50 = 0.347 μM | 21634429 | |
Glioma (HF2303) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF2476) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF2876) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF2885) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF3013) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF2381) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
Glioma (HF2790) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | |
HepG2 | Cytotoxicity assay | 48 hrs | EC50 = 0.01 μM | 29800827 | |
HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 19422206 | |
HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 21973101 | |
CEM | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | |
U266 | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | |
K562 | Antiproliferative assay | 72 hrs | GI50 = 0.007 μM | 28441582 | |
DLD1 | Function assay | 6 hrs | IC50 = 0.0002 μM | 22206869 | |
DLD1 | Function assay | 6 hrs | IC50 = 0.0009 μM | 22206869 | |
HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.001 μM | 28634039 | |
HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.0014 μM | 27769033 | |
HepG2 | Antiproliferative assay | 72 hrs | IC50 = 0.00161 μM | 27769033 | |
SKOV3 | Antiproliferative assay | 72 hrs | IC50 = 0.00162 μM | 27769033 | |
DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.002 μM | 23031590 | |
U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00245 μM | 19537716 | |
A549 | Antiproliferative assay | 72 hrs | IC50 = 0.0025 μM | 28182990 | |
HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0032 μM | 28182990 | |
RPMI18226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | |
HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | |
RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.00388 μM | 26965867 | |
HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 27769033 | |
U266 | Function assay | 1 hr | IC50 = 0.004 μM | 28441582 | |
HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 28634039 | |
SEM | Function assay | 2 hrs | IC50 = 0.00443 μM | 30365892 | |
HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0055 μM | 19537716 | |
U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00573 μM | 26965867 | |
MGC803 | Antiproliferative assay | 72 hrs | IC50 = 0.005782 μM | 27769033 | |
GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.006 μM | 23031590 | |
ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00607 μM | 26965867 | |
SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0061 μM | 20158184 | |
MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.0065 μM | 28182990 | |
HL60 | Function assay | 2 hrs | IC50 = 0.00667 μM | 30365892 | |
A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0067 μM | 20158184 | |
RPMI8226 | Antiproliferative assay | 72 hrs | IC50 = 0.0067 μM | 28182990 | |
5TGM1 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.00678 μM | 24119559 | |
HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0069 μM | 19747832 | |
PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 20158184 | |
DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 23031590 | |
HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0071 μM | 20158184 | |
MKN45 | Antiproliferative assay | 72 hrs | IC50 = 0.00715 μM | 27769033 | |
HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0075 μM | 20158184 | |
HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0076 μM | 27769033 | |
RPMI8226 | Cytotoxic activity against human | 72 hrs | IC50 = 0.00796 μM | 24767818 | |
HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | |
MGC803 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | |
SKOV3/TR | Function assay | 4 days | IC50 = 0.008 μM | 29767973 | |
PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0083 μM | 21077681 | |
U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0088 μM | 20158184 | |
RPMI8226 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.0095 μM | 24119559 | |
ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00957 μM | 29934218 | |
HEK293 | Function assay | 3 hrs | IC50 = 0.01 μM | 20875739 | |
HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.01 μM | 23547757 | |
NCI-H929 | Cytotoxicity assay | 72 hrs | IC50 = 0.01085 μM | 24767818 | |
CCRF-CEM | Antiproliferative assay | 72 hrs | IC50 = 0.011 μM | 26231162 | |
RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0112 μM | 29934218 | |
U266B1 | Cytotoxicity assay | 72 hrs | IC50 = 0.01163 μM | 29934218 | |
BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0118 μM | 19747832 | |
293T | Antiproliferative assay | 72 hrs | IC50 = 0.012 μM | 28191850 | |
U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0122 μM | 19747832 | |
SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0123 μM | 21077681 | |
SKOV3 | Cytotoxicity assay | 4 days | IC50 = 0.0129 μM | 29767973 | |
A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0139 μM | 21077681 | |
HEK293 | Function assay | 30 mins | IC50 = 0.014 μM | 21044847 | |
RPMI8266 | Antiproliferative assay | 72 hrs | IC50 = 0.0144 μM | 26231162 | |
BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0162 μM | 20158184 | |
MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.01665 μM | 27769033 | |
TOV21G | Antiproliferative assay | 72 hrs | IC50 = 0.0167 μM | 26231162 | |
MDA-MB-231 | Cytotoxicity assay | 72 hrs | IC50 = 0.017 μM | 28634039 | |
BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0194 μM | 21077681 | |
HeLa | Growth inhibition assay | 72 hrs | IC50 = 0.02 μM | 19428245 | |
RKO | Antiproliferative assay | 72 hrs | IC50 = 0.0208 μM | 26231162 | |
MCF7 | Antiproliferative assay | 3 days | IC50 = 0.025 μM | 28557430 | |
Bel7404 | Antiproliferative assay | 72 hrs | IC50 = 0.02504 μM | 27769033 | |
HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0252 μM | 21077681 | |
HEK293 | Function assay | 24 hrs | IC50 = 0.027 μM | 21634429 | |
HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.027 μM | 26231162 | |
SUP-B15 | Function assay | 2 hrs | IC50 = 0.02809 μM | 30365892 | |
A431 | Antiproliferative assay | 72 hrs | IC50 = 0.0282 μM | 26231162 | |
A2780 | Antiproliferative assay | 72 hrs | IC50 = 0.0289 μM | 28182990 | |
HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 27769033 | |
HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 28634039 | |
HEK293 | Function assay | 6 hrs | IC50 = 0.03 μM | 28919340 | |
WM266.4 | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 22206869 | |
GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 23031590 | |
HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0375 μM | 19537716 | |
95-D | Cytotoxicity assay | 72 hrs | IC50 = 0.038 μM | 28634039 | |
95-D | Antiproliferative assay | 72 hrs | IC50 = 0.03818 μM | 27769033 | |
SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.05 μM | 19537716 | |
KB | Cytotoxicity assay | 72 hrs | IC50 = 0.0595 μM | 19537716 | |
SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0668 μM | 21077681 | |
SW1990 | Antiproliferative assay | 72 hrs | IC50 = 0.07906 μM | 27769033 | |
HeLa | Cytotoxicity assay | 72 hrs | IC50 = 0.092 μM | 19537716 | |
A549 | Antiproliferative assay | 72 hrs | IC50 = 0.092 μM | 28191850 | |
H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.115 μM | 19537716 | |
SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.13 μM | 19537716 | |
SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.151 μM | 20158184 | |
A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.255 μM | 19537716 | |
HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 27769033 | |
HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 28634039 | |
H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.78 μM | 20158184 | |
BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 0.88 μM | 19537716 | |
MCF7 | Antiproliferative assay | 72 hrs | IC50 = 18.37 μM | 29426629 | |
A549 | Antiproliferative assay | 72 hrs | IC50 = 2.13573 μM | 27769033 | |
A549 | Cytotoxicity assay | 72 hrs | IC50 = 2.14 μM | 28634039 | |
BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 2.89 μM | 19747832 | |
MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 3.125 μM | 29426629 | |
BCG823 | Cytotoxicity assay | 72 hrs | IC50 = 3.29 μM | 20158184 | |
A549 | Antiproliferative assay | 72 hrs | IC50 = 9.318 μM | 29426629 | |
Calu6 | Cytotoxicity assay | 72 hrs | LC50 = 0.0061 μM | 20875739 | |
HEK293T | Antiproliferative assay | 48 hrs | LC50 = 0.016 μM | 29843100 | |
LO2 | Antiproliferative assay | 48 hrs | LC50 = 0.398 μM | 29843100 | |
NCI-H929 | Cytotoxicity assay | 48 hrs | LD50 = 0.0066 μM | 27994734 | |
U266 | Cytotoxicity assay | 48 hrs | LD50 = 0.018 μM | 27994734 | |
LCL | Cytotoxicity assay | 48 hrs | LD50 = 0.02 μM | 27994734 | |
MDA-MB-468 | Cytotoxicity assay | 48 hrs | LD50 = 0.037 μM | 27994734 | |
RD-ES | Cytotoxicity assay | 48 hrs | LD50 = 0.04 μM | 27994734 | |
WE68 | Cytotoxicity assay | 48 hrs | LD50 = 0.1 μM | 27994734 | |
IMR90 | Cytotoxicity assay | 48 hrs | LD50 = 0.13 μM | 27994734 | |
KGN | Cytotoxicity assay | 48 hrs | LD50 = 0.18 μM | 27994734 | |
HNDF | Cytotoxicity assay | 48 hrs | LD50 = 0.48 μM | 27994734 | |
MCF10A | Cytotoxicity assay | 48 hrs | LD50 = 1.5 μM | 27994734 | |
SKOV3 | Cytotoxicity assay | 48 hrs | LD50 = 1.6 μM | 27994734 | |
MCF7 | Cytotoxicity assay | 48 hrs | LD50 = 9.8 μM | 27994734 | |
HCT116 | Cell cycle assay | 24 hrs | Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining-based flow cytometric analysis | 23547757 | |
K-562 | Growth Inhibition Assay | IC50=4.12 nM | SANGER | ||
NCI-H1648 | Growth Inhibition Assay | IC50=4.13 nM | SANGER | ||
OMC-1 | Growth Inhibition Assay | IC50=4.18 nM | SANGER | ||
LB647-SCLC | Growth Inhibition Assay | IC50=4.22 nM | SANGER | ||
TE-12 | Growth Inhibition Assay | IC50=4.25 nM | SANGER | ||
NOMO-1 | Growth Inhibition Assay | IC50=4.33 nM | SANGER | ||
Raji | Growth Inhibition Assay | IC50=4.46 nM | SANGER | ||
NALM-6 | Growth Inhibition Assay | IC50=4.49 nM | SANGER | ||
HL-60 | Growth Inhibition Assay | IC50=4.67 nM | SANGER | ||
IST-SL1 | Growth Inhibition Assay | IC50=4.68 nM | SANGER | ||
MHH-PREB-1 | Growth Inhibition Assay | IC50=4.86 nM | SANGER | ||
MHH-NB-11 | Growth Inhibition Assay | IC50=4.91 nM | SANGER | ||
JiyoyeP-2003 | Growth Inhibition Assay | IC50=5 nM | SANGER | ||
SBC-1 | Growth Inhibition Assay | IC50=5.01 nM | SANGER | ||
CHP-126 | Growth Inhibition Assay | IC50=5.06 nM | SANGER | ||
LU-139 | Growth Inhibition Assay | IC50=5.13 nM | SANGER | ||
NCI-SNU-5 | Growth Inhibition Assay | IC50=5.17 nM | SANGER | ||
SW962 | Growth Inhibition Assay | IC50=5.21 nM | SANGER | ||
EW-1 | Growth Inhibition Assay | IC50=5.31 nM | SANGER | ||
NCI-H1417 | Growth Inhibition Assay | IC50=5.51 nM | SANGER | ||
LU-65 | Growth Inhibition Assay | IC50=5.84 nM | SANGER | ||
D-502MG | Growth Inhibition Assay | IC50=6.37 nM | SANGER | ||
BC-3 | Growth Inhibition Assay | IC50=6.61 nM | SANGER | ||
GDM-1 | Growth Inhibition Assay | IC50=6.77 nM | SANGER | ||
NCI-H2196 | Growth Inhibition Assay | IC50=6.8 nM | SANGER | ||
NB1 | Growth Inhibition Assay | IC50=6.88 nM | SANGER | ||
NCI-H345 | Growth Inhibition Assay | IC50=7.2 nM | SANGER | ||
SU-DHL-1 | Growth Inhibition Assay | IC50=7.24 nM | SANGER | ||
JVM-2 | Growth Inhibition Assay | IC50=7.28 nM | SANGER | ||
LU-134-A | Growth Inhibition Assay | IC50=7.39 nM | SANGER | ||
NCI-H1694 | Growth Inhibition Assay | IC50=7.58 nM | SANGER | ||
NCI-SNU-16 | Growth Inhibition Assay | IC50=7.65 nM | SANGER | ||
L-363 | Growth Inhibition Assay | IC50=7.7 nM | SANGER | ||
KG-1 | Growth Inhibition Assay | IC50=7.94 nM | SANGER | ||
MN-60 | Growth Inhibition Assay | IC50=8.14 nM | SANGER | ||
NB6 | Growth Inhibition Assay | IC50=8.48 nM | SANGER | ||
MLMA | Growth Inhibition Assay | IC50=8.85 nM | SANGER | ||
ATN-1 | Growth Inhibition Assay | IC50=8.89 nM | SANGER | ||
SK-NEP-1 | Growth Inhibition Assay | IC50=9.01 nM | SANGER | ||
DMS-114 | Growth Inhibition Assay | IC50=9.62 nM | SANGER | ||
CTB-1 | Growth Inhibition Assay | IC50=9.67 nM | SANGER | ||
NCI-H2081 | Growth Inhibition Assay | IC50=10.09 nM | SANGER | ||
ES5 | Growth Inhibition Assay | IC50=10.38 nM | SANGER | ||
HCC1599 | Growth Inhibition Assay | IC50=11.91 nM | SANGER | ||
NCI-H23 | Growth Inhibition Assay | IC50=12.12 nM | SANGER | ||
NCI-H1581 | Growth Inhibition Assay | IC50=12.28 nM | SANGER | ||
JVM-3 | Growth Inhibition Assay | IC50=12.99 nM | SANGER | ||
NCI-SNU-1 | Growth Inhibition Assay | IC50=13.19 nM | SANGER | ||
NB7 | Growth Inhibition Assay | IC50=15.92 nM | SANGER | ||
JAR | Growth Inhibition Assay | IC50=16.13 nM | SANGER | ||
TGW | Growth Inhibition Assay | IC50=16.48 nM | SANGER | ||
U-87-MG | Growth Inhibition Assay | IC50=16.76 nM | SANGER | ||
NCI-H1436 | Growth Inhibition Assay | IC50=17.01 nM | SANGER | ||
GOTO | Growth Inhibition Assay | IC50=17.06 nM | SANGER | ||
COLO-800 | Growth Inhibition Assay | IC50=17.64 nM | SANGER | ||
MFM-223 | Growth Inhibition Assay | IC50=17.91 nM | SANGER | ||
EW-18 | Growth Inhibition Assay | IC50=17.96 nM | SANGER | ||
NB14 | Growth Inhibition Assay | IC50=17.98 nM | SANGER | ||
EB2 | Growth Inhibition Assay | IC50=18.08 nM | SANGER | ||
EoL-1- | Growth Inhibition Assay | IC50=18.31 nM | SANGER | ||
NCCIT | Growth Inhibition Assay | IC50=18.36 nM | SANGER | ||
DG-75 | Growth Inhibition Assay | IC50=18.61 nM | SANGER | ||
HCC2218 | Growth Inhibition Assay | IC50=19.5 nM | SANGER | ||
TE-6 | Growth Inhibition Assay | IC50=20.08 nM | SANGER | ||
SF539 | Growth Inhibition Assay | IC50=20.67 nM | SANGER | ||
NCI-H446 | Growth Inhibition Assay | IC50=21.18 nM | SANGER | ||
IST-MES1 | Growth Inhibition Assay | IC50=22.77 nM | SANGER | ||
NCI-H82 | Growth Inhibition Assay | IC50=23.02 nM | SANGER | ||
HCC2157 | Growth Inhibition Assay | IC50=23.13 nM | SANGER | ||
EW-12 | Growth Inhibition Assay | IC50=23.17 nM | SANGER | ||
SIMA | Growth Inhibition Assay | IC50=23.38 nM | SANGER | ||
DOHH-2 | Growth Inhibition Assay | IC50=23.45 nM | SANGER | ||
IM-9 | Growth Inhibition Assay | IC50=23.54 nM | SANGER | ||
EC-GI-10 | Growth Inhibition Assay | IC50=24.23 nM | SANGER | ||
HDLM-2 | Growth Inhibition Assay | IC50=24.54 nM | SANGER | ||
LS-1034 | Growth Inhibition Assay | IC50=25.75 nM | SANGER | ||
REH | Growth Inhibition Assay | IC50=26.41 nM | SANGER | ||
LU-165 | Growth Inhibition Assay | IC50=26.72 nM | SANGER | ||
NH-12 | Growth Inhibition Assay | IC50=27.67 nM | SANGER | ||
WSU-NHL | Growth Inhibition Assay | IC50=28.39 nM | SANGER | ||
ECC4 | Growth Inhibition Assay | IC50=28.79 nM | SANGER | ||
OCI-AML2 | Growth Inhibition Assay | IC50=29.69 nM | SANGER | ||
EW-3 | Growth Inhibition Assay | IC50=30.59 nM | SANGER | ||
NCI-H526 | Growth Inhibition Assay | IC50=32.54 nM | SANGER | ||
NCI-H719 | Growth Inhibition Assay | IC50=34.31 nM | SANGER | ||
KARPAS-422 | Growth Inhibition Assay | IC50=35.04 nM | SANGER | ||
SK-MEL-1 | Growth Inhibition Assay | IC50=35.17 nM | SANGER | ||
ES3 | Growth Inhibition Assay | IC50=35.19 nM | SANGER | ||
UACC-812 | Growth Inhibition Assay | IC50=35.44 nM | SANGER | ||
C8166 | Growth Inhibition Assay | IC50=35.7 nM | SANGER | ||
MDA-MB-134-VI | Growth Inhibition Assay | IC50=35.87 nM | SANGER | ||
D-283MED | Growth Inhibition Assay | IC50=37.79 nM | SANGER | ||
SHP-77 | Growth Inhibition Assay | IC50=38.03 nM | SANGER | ||
NCI-H2227 | Growth Inhibition Assay | IC50=40.49 nM | SANGER | ||
SKM-1 | Growth Inhibition Assay | IC50=42.63 nM | SANGER | ||
L-428 | Growth Inhibition Assay | IC50=43.86 nM | SANGER | ||
RPMI-6666 | Growth Inhibition Assay | IC50=45.89 nM | SANGER | ||
NCI-H716 | Growth Inhibition Assay | IC50=48.81 nM | SANGER | ||
DMS-79 | Growth Inhibition Assay | IC50=50.71 nM | SANGER | ||
RS4-11 | Growth Inhibition Assay | IC50=50.88 nM | SANGER | ||
NCI-H720 | Growth Inhibition Assay | IC50=51.11 nM | SANGER | ||
MC-CAR | Growth Inhibition Assay | IC50=51.52 nM | SANGER | ||
TALL-1 | Growth Inhibition Assay | IC50=53.91 nM | SANGER | ||
NCI-N87 | Growth Inhibition Assay | IC50=54.18 nM | SANGER | ||
P30-OHK | Growth Inhibition Assay | IC50=54.61 nM | SANGER | ||
LP-1 | Growth Inhibition Assay | IC50=61.28 nM | SANGER | ||
YT | Growth Inhibition Assay | IC50=61.8 nM | SANGER | ||
MRK-nu-1 | Growth Inhibition Assay | IC50=61.82 nM | SANGER | ||
BT-474 | Growth Inhibition Assay | IC50=65 nM | SANGER | ||
NCI-H322M | Growth Inhibition Assay | IC50=66.11 nM | SANGER | ||
NCI-H128 | Growth Inhibition Assay | IC50=74.77 nM | SANGER | ||
KMS-12-PE | Growth Inhibition Assay | IC50=76.24 nM | SANGER | ||
KP-N-YS | Growth Inhibition Assay | IC50=76.74 nM | SANGER | ||
ALL-PO | Growth Inhibition Assay | IC50=77.66 nM | SANGER | ||
EW-13 | Growth Inhibition Assay | IC50=77.76 nM | SANGER | ||
EW-11 | Growth Inhibition Assay | IC50=78.52 nM | SANGER | ||
SK-N-FI | Growth Inhibition Assay | IC50=80.2 nM | SANGER | ||
CAL-148 | Growth Inhibition Assay | IC50=81.84 nM | SANGER | ||
RL | Growth Inhibition Assay | IC50=86.09 nM | SANGER | ||
AM-38 | Growth Inhibition Assay | IC50=88.08 nM | SANGER | ||
RH-1 | Growth Inhibition Assay | IC50=99.85 nM | SANGER | ||
NCI-H1770 | Growth Inhibition Assay | IC50=102.49 nM | SANGER | ||
SIG-M5 | Growth Inhibition Assay | IC50=105.06 nM | SANGER | ||
GR-ST | Growth Inhibition Assay | IC50=113.34 nM | SANGER | ||
ST486 | Growth Inhibition Assay | IC50=114.06 nM | SANGER | ||
NCI-H1650 | Growth Inhibition Assay | IC50=115.29 nM | SANGER | ||
MHH-CALL-2 | Growth Inhibition Assay | IC50=115.7 nM | SANGER | ||
BV-173 | Growth Inhibition Assay | IC50=122.71 nM | SANGER | ||
MC116 | Growth Inhibition Assay | IC50=148.85 nM | SANGER | ||
NCI-H524 | Growth Inhibition Assay | IC50=159.1 nM | SANGER | ||
SCLC-21H | Growth Inhibition Assay | IC50=159.41 nM | SANGER | ||
NCI-H1304 | Growth Inhibition Assay | IC50=169.21 nM | SANGER | ||
NCI-H510A | Growth Inhibition Assay | IC50=185.37 nM | SANGER | ||
NCI-H209 | Growth Inhibition Assay | IC50=196.52 nM | SANGER | ||
KM-H2 | Growth Inhibition Assay | IC50=197.05 nM | SANGER | ||
NCI-H1395 | Growth Inhibition Assay | IC50=210.13 nM | SANGER | ||
NCI-H1155 | Growth Inhibition Assay | IC50=230.32 nM | SANGER | ||
COR-L279 | Growth Inhibition Assay | IC50=252.17 nM | SANGER | ||
NCI-H1299 | Growth Inhibition Assay | IC50=261.71 nM | SANGER | ||
EW-22 | Growth Inhibition Assay | IC50=263.75 nM | SANGER | ||
SK-MEL-2 | Growth Inhibition Assay | IC50=281.9 nM | SANGER | ||
KASUMI-1 | Growth Inhibition Assay | IC50=283.05 nM | SANGER | ||
NCI-H187 | Growth Inhibition Assay | IC50=287.08 nM | SANGER | ||
NCI-H2171 | Growth Inhibition Assay | IC50=288.92 nM | SANGER | ||
LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=295.26 nM | SANGER | ||
NCI-H1522 | Growth Inhibition Assay | IC50=307.05 nM | SANGER | ||
SCH | Growth Inhibition Assay | IC50=322.22 nM | SANGER | ||
THP-1 | Growth Inhibition Assay | IC50=322.6 nM | SANGER | ||
SNU-C1 | Growth Inhibition Assay | IC50=362.09 nM | SANGER | ||
CA46 | Growth Inhibition Assay | IC50=373.63 nM | SANGER | ||
NCI-H1963 | Growth Inhibition Assay | IC50=386.19 nM | SANGER | ||
DEL | Growth Inhibition Assay | IC50=391.27 nM | SANGER | ||
TUR | Growth Inhibition Assay | IC50=396.61 nM | SANGER | ||
NCI-H226 | Growth Inhibition Assay | IC50=403.23 nM | SANGER | ||
COLO-668 | Growth Inhibition Assay | IC50=403.57 nM | SANGER | ||
CPC-N | Growth Inhibition Assay | IC50=403.77 nM | SANGER | ||
NCI-H889 | Growth Inhibition Assay | IC50=461.92 nM | SANGER | ||
J-RT3-T3-5 | Growth Inhibition Assay | IC50=532.57 nM | SANGER | ||
MSTO-211H | Growth Inhibition Assay | IC50=574.26 nM | SANGER | ||
SCC-15 | Growth Inhibition Assay | IC50=667.47 nM | SANGER | ||
SUP-T1 | Growth Inhibition Assay | IC50=686.04 nM | SANGER | ||
DMS-153 | Growth Inhibition Assay | IC50=746.83 nM | SANGER | ||
MS-1 | Growth Inhibition Assay | IC50=759.42 nM | SANGER | ||
TC-YIK | Growth Inhibition Assay | IC50=781.01 nM | SANGER | ||
RPMI-8866 | Growth Inhibition Assay | IC50=1006.28 μM | SANGER | ||
KY821 | Growth Inhibition Assay | IC50=1036.04 μM | SANGER | ||
P31-FUJ | Growth Inhibition Assay | IC50=1112.75 μM | SANGER | ||
COLO-824 | Growth Inhibition Assay | IC50=1261.78 μM | SANGER | ||
U-698-M | Growth Inhibition Assay | IC50=2262.15 μM | SANGER | ||
TE-441-T | Growth Inhibition Assay | IC50=2521.7 μM | SANGER | ||
IMR-5 | Growth Inhibition Assay | IC50=3409.62 μM | SANGER | ||
NCI-H1838 | Growth Inhibition Assay | IC50=4186.32 μM | SANGER | ||
NCI-H2141 | Growth Inhibition Assay | IC50=4.05 nM | SANGER | ||
HD-MY-Z | Growth Inhibition Assay | IC50=3.93 nM | SANGER | ||
RCC10RGB | Growth Inhibition Assay | IC50=3.93 nM | SANGER | ||
COLO-320-HSR | Growth Inhibition Assay | IC50=3.92 nM | SANGER | ||
RL95-2 | Growth Inhibition Assay | IC50=3.79 nM | SANGER | ||
LC-1F | Growth Inhibition Assay | IC50=3.74 nM | SANGER | ||
NMC-G1 | Growth Inhibition Assay | IC50=3.68 nM | SANGER | ||
COLO-684 | Growth Inhibition Assay | IC50=3.66 nM | SANGER | ||
DJM-1 | Growth Inhibition Assay | IC50=3.63 nM | SANGER | ||
EVSA-T | Growth Inhibition Assay | IC50=3.6 nM | SANGER | ||
no-11 | Growth Inhibition Assay | IC50=3.55 nM | SANGER | ||
MZ1-PC | Growth Inhibition Assay | IC50=3.54 nM | SANGER | ||
HCC1187 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | ||
KARPAS-45 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | ||
RPMI-8402 | Growth Inhibition Assay | IC50=3.5 nM | SANGER | ||
LOXIMVI | Growth Inhibition Assay | IC50=3.5 nM | SANGER | ||
MEG-01 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | ||
LAMA-84 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | ||
COR-L88 | Growth Inhibition Assay | IC50=3.47 nM | SANGER | ||
TE-15 | Growth Inhibition Assay | IC50=3.43 nM | SANGER | ||
DB | Growth Inhibition Assay | IC50=3.41 nM | SANGER | ||
LB996-RCC | Growth Inhibition Assay | IC50=3.4 nM | SANGER | ||
NEC8 | Growth Inhibition Assay | IC50=3.35 nM | SANGER | ||
SK-N-DZ | Growth Inhibition Assay | IC50=3.26 nM | SANGER | ||
CW-2 | Growth Inhibition Assay | IC50=3.21 nM | SANGER | ||
SK-PN-DW | Growth Inhibition Assay | IC50=3.14 nM | SANGER | ||
CGTH-W-1 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | ||
MONO-MAC-6 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | ||
KARPAS-299 | Growth Inhibition Assay | IC50=3.06 nM | SANGER | ||
HT | Growth Inhibition Assay | IC50=3.02 nM | SANGER | ||
SW954 | Growth Inhibition Assay | IC50=2.9 nM | SANGER | ||
MOLT-16 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | ||
C2BBe1 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | ||
ETK-1 | Growth Inhibition Assay | IC50=2.84 nM | SANGER | ||
CTV-1 | Growth Inhibition Assay | IC50=2.8 nM | SANGER | ||
EW-16 | Growth Inhibition Assay | IC50=2.75 nM | SANGER | ||
Mo-T | Growth Inhibition Assay | IC50=2.74 nM | SANGER | ||
EB-3 | Growth Inhibition Assay | IC50=2.66 nM | SANGER | ||
LB1047-RCC | Growth Inhibition Assay | IC50=2.57 nM | SANGER | ||
KNS-81-FD | Growth Inhibition Assay | IC50=2.48 nM | SANGER | ||
NB69 | Growth Inhibition Assay | IC50=2.46 nM | SANGER | ||
NCI-H64 | Growth Inhibition Assay | IC50=2.44 nM | SANGER | ||
KU812 | Growth Inhibition Assay | IC50=2.42 nM | SANGER | ||
NCI-H748 | Growth Inhibition Assay | IC50=2.39 nM | SANGER | ||
ARH-77 | Growth Inhibition Assay | IC50=2.38 nM | SANGER | ||
SCC-3 | Growth Inhibition Assay | IC50=2.37 nM | SANGER | ||
RPMI-8226 | Growth Inhibition Assay | IC50=2.35 nM | SANGER | ||
NB10 | Growth Inhibition Assay | IC50=2.32 nM | SANGER | ||
BC-1 | Growth Inhibition Assay | IC50=2.31 nM | SANGER | ||
NB5 | Growth Inhibition Assay | IC50=2.27 nM | SANGER | ||
KMOE-2 | Growth Inhibition Assay | IC50=2.23 nM | SANGER | ||
SJSA-1 | Growth Inhibition Assay | IC50=2.21 nM | SANGER | ||
ES4 | Growth Inhibition Assay | IC50=2.16 nM | SANGER | ||
KGN | Growth Inhibition Assay | IC50=2.15 nM | SANGER | ||
EKVX | Growth Inhibition Assay | IC50=2.14 nM | SANGER | ||
MOLT-4 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | ||
KE-37 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | ||
HH | Growth Inhibition Assay | IC50=2.13 nM | SANGER | ||
GT3TKB | Growth Inhibition Assay | IC50=2.12 nM | SANGER | ||
BL-70 | Growth Inhibition Assay | IC50=2.12 nM | SANGER | ||
NOS-1 | Growth Inhibition Assay | IC50=2.11 nM | SANGER | ||
EW-24 | Growth Inhibition Assay | IC50=2.08 nM | SANGER | ||
LAN-6 | Growth Inhibition Assay | IC50=2.05 nM | SANGER | ||
NB17 | Growth Inhibition Assay | IC50=2.04 nM | SANGER | ||
LS-123 | Growth Inhibition Assay | IC50=2.02 nM | SANGER | ||
NB13 | Growth Inhibition Assay | IC50=2 nM | SANGER | ||
NKM-1 | Growth Inhibition Assay | IC50=2 nM | SANGER | ||
697 | Growth Inhibition Assay | IC50=1.99 nM | SANGER | ||
BE-13 | Growth Inhibition Assay | IC50=1.93 nM | SANGER | ||
MPP-89 | Growth Inhibition Assay | IC50=1.89 nM | SANGER | ||
Becker | Growth Inhibition Assay | IC50=1.83 nM | SANGER | ||
MV-4-11 | Growth Inhibition Assay | IC50=1.82 nM | SANGER | ||
GB-1 | Growth Inhibition Assay | IC50=1.81 nM | SANGER | ||
NCI-H1092 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | ||
NCI-H2126 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | ||
LC4-1 | Growth Inhibition Assay | IC50=1.79 nM | SANGER | ||
U-266 | Growth Inhibition Assay | IC50=1.76 nM | SANGER | ||
KURAMOCHI | Growth Inhibition Assay | IC50=1.72 nM | SANGER | ||
TGBC1TKB | Growth Inhibition Assay | IC50=1.71 nM | SANGER | ||
EHEB | Growth Inhibition Assay | IC50=1.67 nM | SANGER | ||
GCIY | Growth Inhibition Assay | IC50=1.62 nM | SANGER | ||
HEL | Growth Inhibition Assay | IC50=1.61 nM | SANGER | ||
NB12 | Growth Inhibition Assay | IC50=1.56 nM | SANGER | ||
NCI-H69 | Growth Inhibition Assay | IC50=1.54 nM | SANGER | ||
LS-411N | Growth Inhibition Assay | IC50=1.53 nM | SANGER | ||
PF-382 | Growth Inhibition Assay | IC50=1.47 nM | SANGER | ||
CAS-1 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | ||
L-540 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | ||
ECC12 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | ||
DU-4475 | Growth Inhibition Assay | IC50=1.36 nM | SANGER | ||
OPM-2 | Growth Inhibition Assay | IC50=1.33 nM | SANGER | ||
IST-SL2 | Growth Inhibition Assay | IC50=1.31 nM | SANGER | ||
Calu-6 | Growth Inhibition Assay | IC50=1.29 nM | SANGER | ||
CMK | Growth Inhibition Assay | IC50=1.29 nM | SANGER | ||
A3-KAW | Growth Inhibition Assay | IC50=1.28 nM | SANGER | ||
K5 | Growth Inhibition Assay | IC50=1.28 nM | SANGER | ||
KM12 | Growth Inhibition Assay | IC50=1.27 nM | SANGER | ||
SR | Growth Inhibition Assay | IC50=1.25 nM | SANGER | ||
BL-41 | Growth Inhibition Assay | IC50=1.25 nM | SANGER | ||
Daudi | Growth Inhibition Assay | IC50=1.22 nM | SANGER | ||
NCI-H1882 | Growth Inhibition Assay | IC50=1.2 nM | SANGER | ||
TE-8 | Growth Inhibition Assay | IC50=1.19 nM | SANGER | ||
HAL-01 | Growth Inhibition Assay | IC50=1.18 nM | SANGER | ||
EM-2 | Growth Inhibition Assay | IC50=1.16 nM | SANGER | ||
CCRF-CEM | Growth Inhibition Assay | IC50=1.13 nM | SANGER | ||
D-392MG | Growth Inhibition Assay | IC50=1.1 nM | SANGER | ||
MZ7-mel | Growth Inhibition Assay | IC50=1.09 nM | SANGER | ||
VA-ES-BJ | Growth Inhibition Assay | IC50=1.09 nM | SANGER | ||
SK-MM-2 | Growth Inhibition Assay | IC50=1.09 nM | SANGER | ||
LC-2-ad | Growth Inhibition Assay | IC50=1.08 nM | SANGER | ||
RKO | Growth Inhibition Assay | IC50=1.06 nM | SANGER | ||
TE-10 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | ||
TE-1 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | ||
PSN1 | Growth Inhibition Assay | IC50=1.01 nM | SANGER | ||
SW872 | Growth Inhibition Assay | IC50=0.996 nM | SANGER | ||
HC-1 | Growth Inhibition Assay | IC50=0.975 nM | SANGER | ||
KALS-1 | Growth Inhibition Assay | IC50=0.925 nM | SANGER | ||
SF268 | Growth Inhibition Assay | IC50=0.923 nM | SANGER | ||
IST-MEL1 | Growth Inhibition Assay | IC50=0.917 nM | SANGER | ||
RXF393 | Growth Inhibition Assay | IC50=0.914 nM | SANGER | ||
SNB75 | Growth Inhibition Assay | IC50=0.912 nM | SANGER | ||
NCI-H1355 | Growth Inhibition Assay | IC50=0.895 nM | SANGER | ||
TE-5 | Growth Inhibition Assay | IC50=0.865 nM | SANGER | ||
QIMR-WIL | Growth Inhibition Assay | IC50=0.889 nM | SANGER | ||
SK-LMS-1 | Growth Inhibition Assay | IC50=0.854 nM | SANGER | ||
SW684 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | ||
ML-2 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | ||
D-263MG | Growth Inhibition Assay | IC50=0.807 nM | SANGER | ||
LB2241-RCC | Growth Inhibition Assay | IC50=0.804 nM | SANGER | ||
GI-1 | Growth Inhibition Assay | IC50=0.764 nM | SANGER | ||
ES7 | Growth Inhibition Assay | IC50=0.766 nM | SANGER | ||
LS-513 | Growth Inhibition Assay | IC50=0.739 nM | SANGER | ||
KINGS-1 | Growth Inhibition Assay | IC50=0.722 nM | SANGER | ||
UACC-257 | Growth Inhibition Assay | IC50=0.71 nM | SANGER | ||
LB373-MEL-D | Growth Inhibition Assay | IC50=0.7 nM | SANGER | ||
SF126 | Growth Inhibition Assay | IC50=0.701 nM | SANGER | ||
Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=0.693 nM | SANGER | ||
TK10 | Growth Inhibition Assay | IC50=0.679 nM | SANGER | ||
D-336MG | Growth Inhibition Assay | IC50=0.657 nM | SANGER | ||
BB49-HNC | Growth Inhibition Assay | IC50=0.652 nM | SANGER | ||
HOP-62 | Growth Inhibition Assay | IC50=0.647 nM | SANGER | ||
LB831-BLC | Growth Inhibition Assay | IC50=0.641 nM | SANGER | ||
GI-ME-N | Growth Inhibition Assay | IC50=0.634 nM | SANGER | ||
A4-Fuk | Growth Inhibition Assay | IC50=0.623 nM | SANGER | ||
HT-144 | Growth Inhibition Assay | IC50=0.576 nM | SANGER | ||
COLO-829 | Growth Inhibition Assay | IC50=0.614 nM | SANGER | ||
NCI-H747 | Growth Inhibition Assay | IC50=0.539 nM | SANGER | ||
CESS | Growth Inhibition Assay | IC50=0.538 nM | SANGER | ||
HUTU-80 | Growth Inhibition Assay | IC50=0.533 nM | SANGER | ||
DSH1 | Growth Inhibition Assay | IC50=0.48 nM | SANGER | ||
LB771-HNC | Growth Inhibition Assay | IC50=0.474 nM | SANGER | ||
CP66-MEL | Growth Inhibition Assay | IC50=0.473 nM | SANGER | ||
OCUB-M | Growth Inhibition Assay | IC50=0.447 nM | SANGER | ||
MFH-ino | Growth Inhibition Assay | IC50=0.443 nM | SANGER | ||
OS-RC-2 | Growth Inhibition Assay | IC50=0.44 nM | SANGER | ||
HCE-T | Growth Inhibition Assay | IC50=0.439 nM | SANGER | ||
ES1 | Growth Inhibition Assay | IC50=0.43 nM | SANGER | ||
LB2518-MEL | Growth Inhibition Assay | IC50=0.425 nM | SANGER | ||
ACN | Growth Inhibition Assay | IC50=0.417 nM | SANGER | ||
D-247MG | Growth Inhibition Assay | IC50=0.413 nM | SANGER | ||
HCC2998 | Growth Inhibition Assay | IC50=0.412 nM | SANGER | ||
MZ2-MEL | Growth Inhibition Assay | IC50=0.407 nM | SANGER | ||
ES8 | Growth Inhibition Assay | IC50=0.4 nM | SANGER | ||
A388 | Growth Inhibition Assay | IC50=0.356 nM | SANGER | ||
KS-1 | Growth Inhibition Assay | IC50=0.34 nM | SANGER | ||
BB30-HNC | Growth Inhibition Assay | IC50=0.335 nM | SANGER | ||
ONS-76 | Growth Inhibition Assay | IC50=0.33 nM | SANGER | ||
D-542MG | Growth Inhibition Assay | IC50=0.329 nM | SANGER | ||
BB65-RCC | Growth Inhibition Assay | IC50=0.304 nM | SANGER | ||
LOUCY | Growth Inhibition Assay | IC50=0.293 nM | SANGER | ||
OVCAR-4 | Growth Inhibition Assay | IC50=0.289 nM | SANGER | ||
LXF-289 | Growth Inhibition Assay | IC50=0.269 nM | SANGER | ||
KNS-42 | Growth Inhibition Assay | IC50=0.258 nM | SANGER | ||
8-MG-BA | Growth Inhibition Assay | IC50=0.25 nM | SANGER | ||
NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=0.243 nM | SANGER | ||
A101D | Growth Inhibition Assay | IC50=0.225 nM | SANGER | ||
MMAC-SF | Growth Inhibition Assay | IC50=0.216 nM | SANGER | ||
no-10 | Growth Inhibition Assay | IC50=0.21 nM | SANGER | ||
A253 | Growth Inhibition Assay | IC50=0.208 nM | SANGER | ||
TE-9 | Growth Inhibition Assay | IC50=0.182 nM | SANGER | ||
SH-4 | Growth Inhibition Assay | IC50=0.173 nM | SANGER | ||
SK-UT-1 | Growth Inhibition Assay | IC50=0.163 nM | SANGER | ||
ES6 | Growth Inhibition Assay | IC50=0.0021 nM | SANGER | ||
Molt4 | Function assay | EC50 = 0.021 μM | 18247547 | ||
Molt4 | Function assay | EC50 = 0.021 μM | 22503349 | ||
RPMI8226 | Growth inhibition assay | GI50 = 0.00023 μM | 24946214 | ||
CCRF-CEM | Growth inhibition assay | GI50 = 0.00035 μM | 24946214 | ||
MDA-MB-435 | Growth inhibition assay | GI50 = 0.00044 μM | 24946214 | ||
MALME-3M | Growth inhibition assay | GI50 = 0.00045 μM | 24946214 | ||
NCI-H226 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | ||
SK-MEL-28 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | ||
A498 | Growth inhibition assay | GI50 = 0.00048 μM | 24946214 | ||
MOLT4 | Growth inhibition assay | GI50 = 0.00051 μM | 24946214 | ||
OVCAR3 | Growth inhibition assay | GI50 = 0.00054 μM | 24946214 | ||
SW620 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | ||
MCF7 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | ||
BT549 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | ||
UACC257 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | ||
SF539 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | ||
HCC2998 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | ||
HCT116 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | ||
T47D | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | ||
CAKI-1 | Growth inhibition assay | GI50 = 0.00066 μM | 24946214 | ||
SK-MEL-5 | Growth inhibition assay | GI50 = 0.00068 μM | 24946214 | ||
RXF393 | Growth inhibition assay | GI50 = 0.00071 μM | 24946214 | ||
LOXIMVI | Growth inhibition assay | GI50 = 0.00078 μM | 24946214 | ||
ACHN | Growth inhibition assay | GI50 = 0.00079 μM | 24946214 | ||
SR | Growth inhibition assay | GI50 = 0.00085 μM | 24946214 | ||
UACC62 | Growth inhibition assay | GI50 = 0.00091 μM | 24946214 | ||
M14 | Growth inhibition assay | GI50 = 0.00093 μM | 24946214 | ||
HT-29 | Growth inhibition assay | GI50 = 0.00095 μM | 24946214 | ||
HOP92 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | ||
NCI-H23 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | ||
TK10 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | ||
Hs 578T | Growth inhibition assay | GI50 = 0.00102 μM | 24946214 | ||
UO31 | Growth inhibition assay | GI50 = 0.00105 μM | 24946214 | ||
SK-MEL-2 | Growth inhibition assay | GI50 = 0.00107 μM | 24946214 | ||
SN12C | Growth inhibition assay | GI50 = 0.0011 μM | 24946214 | ||
K562 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | ||
SF268 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | ||
COLO205 | Growth inhibition assay | GI50 = 0.00123 μM | 24946214 | ||
MDA-MB-231 | Growth inhibition assay | GI50 = 0.00126 μM | 24946214 | ||
NCI-H522 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | ||
786-0 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | ||
MDA-MB-468 | Growth inhibition assay | GI50 = 0.00148 μM | 24946214 | ||
HCT15 | Growth inhibition assay | GI50 = 0.00151 μM | 24946214 | ||
U251 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | ||
OVCAR5 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | ||
KM12 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | ||
SF295 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | ||
DU145 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | ||
HL-60(TB) | Growth inhibition assay | GI50 = 0.0019 μM | 24946214 | ||
OVCAR4 | Growth inhibition assay | GI50 = 0.00195 μM | 24946214 | ||
SNB19 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | ||
SNB75 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | ||
IGROV1 | Growth inhibition assay | GI50 = 0.00224 μM | 24946214 | ||
OVCAR8 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | ||
PC3 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | ||
EKVX | Growth inhibition assay | GI50 = 0.00302 μM | 24946214 | ||
A549/ATCC | Growth inhibition assay | GI50 = 0.00309 μM | 24946214 | ||
HOP62 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | ||
NCI-H460 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | ||
NCI-ADR-RES | Growth inhibition assay | GI50 = 0.0123 μM | 24946214 | ||
SKOV3 | Growth inhibition assay | GI50 = 0.0138 μM | 24946214 | ||
NCI-H322M | Growth inhibition assay | GI50 = 0.0178 μM | 24946214 | ||
A2780 | Cytotoxicity assay | IC50 = 0.0017 μM | 18247547 | ||
RPMI8226 | Cytotoxicity assay | IC50 = 0.0088 μM | 20727746 | ||
HCT116 | Function assay | Inhibition of proteasome in human HCT116 cells assessed as accumulation of p53 by Western blotting analysis | 23547757 | ||
HCT116 | Apoptosis assay | Induction of apoptosis in human HCT116 cells assessed as induction of PARP cleavage by Western blotting analysis | 23547757 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | ||
U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
Daoy | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 29435139 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells | 29435139 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 29435139 | ||
HepG2 | Cell viability assay | HepG2 cells viability qHTS for Zika virus inhibitors | 33229545 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Bortezomib是有效的蛋白酶抑制劑,Ki為0.6 nM。它對腫瘤細胞表現(xiàn)出良好的選擇性。Bortezomib可抑制 NF-κB 并誘導(dǎo) ERK 的磷酸化從而抑制cathepsin B并在卵巢癌和其他固體腫瘤中抑制自噬的催化過程。 | ||||
---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Bortezomib,一種硼酸二肽,是一種26S蛋白酶體的高選擇性可逆抑制劑,其作用于錯誤折疊蛋白的降解,并且對細胞周期的調(diào)控是必要的。暴露于Bortezomib能夠穩(wěn)定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制劑κB-α,這防止了核因子κB誘導(dǎo)的細胞存活途徑的激活。Bortezomib也會促進促凋亡c-Jun-NH2末端激酶,以及內(nèi)質(zhì)網(wǎng)應(yīng)激反應(yīng)的激活。這些細胞蛋白水平的改變導(dǎo)致對增殖,遷移的抑制,和癌細胞凋亡的促進。[2] Bortezomib能夠滲透到細胞,并抑制蛋白酶體介導(dǎo)的細胞內(nèi)長壽蛋白水解,抑制50%蛋白質(zhì)水解的濃度為∼0.1 μM。Bortezomib對衍生自美國國家癌癥研究所(NCI)多重人類腫瘤的一組60個癌細胞系的IC50值為7 nM。PC-3細胞用Bortezomib (100 nM)處理8小時導(dǎo)致細胞積聚在G2-M期,相應(yīng)的G1期細胞數(shù)量減少。Bortezomib在24和48小時殺死PC-3細胞,IC50分別為100和20 nM。Bortezomib治療16-24小時后誘導(dǎo)細胞核縮合。Bortezomib在低至100 nM濃度下以時間依賴的方式導(dǎo)致PARP裂解,在處理24小時后產(chǎn)生效果。[1] |
|||
---|---|---|---|---|
激酶實驗 | 動力學(xué)法 | |||
在典型的動力學(xué)試驗中,2.00 mL試驗緩沖液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL熒光比色皿中,并將比色皿放置于熒光分光光度計的夾套細胞皿座。反應(yīng)溫度通過循環(huán)水浴維持在37℃。反應(yīng)溶液達到熱平衡后(5 分鐘),1 μL?10 μL儲存酶溶液加入培養(yǎng)皿。伴隨AMC 從多肽AMC底物裂解的反應(yīng)進程通過440 nm (λex= 380 nm)下熒光發(fā)射的增加監(jiān)測。 | ||||
細胞實驗 | 細胞系 | 人多發(fā)性骨髓瘤細胞系U266 | ||
濃度 | ~10 μM | |||
孵育時間 | 2天 | |||
方法 | 通過測定細胞吸收 MTT染料的情況而測定 Bortezomib對 MM和 BMSC 生長的抑制情況。每孔使用10 μL 5 mg/mL MTT對培養(yǎng)48小時的細胞進行脈沖處理,至少處理4小時, 隨后加入100 μL 含0.04 N HCl的異丙醇 。使用分光光度計在 570 nm處測定吸光值。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | phospho-PERK / ATF-4 GRP-78 / GADD-34 pro-caspase-12 / pro-caspase-3 pro-caspase-9 p-IκBα / IκBα COX-2 / cIAP2 |
![]() |
15509775 | |
Immunofluorescence | Vimentin Ubiquitin |
![]() |
19010849 | |
Growth inhibition assay | Cell viability |
![]() |
20571067 | |
ELISA | IL-8 |
![]() |
24085292 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | Bortezomib單一用藥的抗癌作用已在多發(fā)性骨髓瘤的異種移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,頭頸癌,和結(jié)腸癌,以及在黑色素瘤中得到證實。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起腫瘤生長延遲,并減少轉(zhuǎn)移數(shù)量。Bortezomib單一用藥, 高達5 mg/kg劑量時顯著降低乳腺癌細胞的存活率。在前列腺癌小鼠異種移植模型中,Bortezomib (1.0 mg/kg,每周一次)用藥4周減少60%腫瘤生長。1.0 mg/kg Bortezomib給藥4周導(dǎo)致胰腺癌小鼠異種移植物生長減少72%或84%,并導(dǎo)致腫瘤細胞凋亡增加。1.0 mg/kg Bortezomib顯著抑制人漿細胞瘤異種移植物生長,增加腫瘤細胞凋亡和總存活率,并減少腫瘤血管生成。[3] |
|
---|---|---|
動物實驗 | Animal Models | 人漿細胞瘤異種移植物RPMI 8226 |
Dosages | 1mg/kg | |
Administration | i.v.,一周兩次,使用4周,然后一周一次 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT05599880 | Recruiting | Relapsed/Refractory Immune Thrombocytopenia |
Seoul National University Hospital |
July 7 2023 | Phase 2 |
NCT05781425 | Recruiting | Chemotherapy-induced Peripheral Neuropathy |
Odense University Hospital|Aarhus University Hospital|Sygehus Lillebaelt|University of Southern Denmark |
May 12 2023 | -- |
NCT05383547 | Unknown status | Bortezomib|Glomerulonephritis|MN|MPGN|FSGS|IgA Nephropathy |
Ruijin Hospital |
August 2 2022 | Not Applicable |
NCT04915248 | Recruiting | Plasmablastic Lymphoma |
Fondazione Italiana Linfomi - ETS|Janssen-Cilag S.p.A. |
July 11 2022 | Phase 2 |
NCT04656951 | Recruiting | Multiple Myeloma |
University of Cologne|Janssen-Cilag G.m.b.H |
June 1 2021 | Phase 2 |
分子量 | 384.24 | 分子式 | C19H25BN4O4 |
CAS號 | 179324-69-7 | SDF | Download Bortezomib SDF |
Smiles | B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O | ||
儲存條件(自收到貨起) | 3年 -20°C(避光) 粉狀 | ||
體外溶解度 |
DMSO : 77 mg/mL ( (200.39 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
回答:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.